Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review (original) (raw)
Related papers
Severe asthma and COVID-19: lessons from the first wave
Journal of Asthma
Objective: Severe asthma is considered a risk factor for SARS-Coronavirus 2 (SARS-CoV-2) infection but scientific evidences are lacking. Methods: we performed a literature search and review based on PubMed database national, international recommendations as well as papers on severe asthmatic patients and their management during SARS-CoV-2 pandemic. Results: the majority of international recommendations, expert panels and editorials provide indications about management of severe asthmatic patients. No published studies evaluated the effects of biologic agents on severe asthmatic patients during SARS-CoV-2 pandemic. Conclusions: the relationship between SARS-CoV-2 and asthma is variable worldwide and severe asthmatic patients were seldom reported in published cohorts. International recommendations suggest maintaining asthma under control to limit exacerbations occurrence, by using all available treatment. The minimum steroid dosage effective to control symptoms should be maintained to avoid exacerbations; biologic agents administration should be regularly scheduled encouraging patient support programmes.
Asthma and COVID-19: What do we know now
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2020
The COVID-19 pandemic has presented challenges in symptomology identification, diagnosis, management and follow-up in common respiratory diseases, and in particular asthma. Research is rapidly ongoing to try and understand how the SARS-CoV-2 virus affects individuals with asthma, as well as, how underlying asthma affects Covid-19 risk, symptomology and prognosis. In light of this unique medical challenge, clinicians are faced with case-by-case based decisions to implement or continue current asthma therapy. This review will discuss the current literature regarding asthma and COVID-19 based on best available evidence at this time
COVID-19 and asthma;what comments we need to know?
2020
BACKGROUND: Asthma is a common chronic inflammatory respiratory disease more common in children. Microbial agents such as viruses are a common trigger of asthma. Coronavirus disease 2019 (COVID-19) is a pandemic disease that could lead to the exacerbation of allergic disorders such as asthma. The aim of this study is to write a narrative review of COVID-19 and asthma condition. Methods: We searched in google scholar, PubMed, and Scopus databases with keywords COVID-19, asthma, corticosteroid, and inhaled steroids. Results: We found a few original articles on the combined subject of asthma and COVID-19. More than 50% of our data is expert comments at valid websites such as https:// www.AAAAI.org or https://ginasthma.org. The typical treatment recommended in the exacerbation of asthma or chronic obstructive pulmonary disease (COPD) included the use of corticosteroids. The routine use of corticosteroids in patients with COVID-19 without obstructive lung disease is not advised, as it ma...
Asthma and COVID-19: a controversial relationship
Virology Journal
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection induces a spectrum of clinical manifestations that depend on the immune response of the patient, i.e., from an asymptomatic form to an inflammatory response with multiorgan deterioration. In some cases, severe cases of SARS-CoV-2 are characterized by an excessive, persistent release of inflammatory mediators known as a cytokine storm. This phenomenon arises from an ineffective T helper (Th)-1 response, which is unable to control the infection and leads to a reinforcement of innate immunity, causing tissue damage. The evolution of the disease produced by SARS-CoV2, known as COVID-19, has been of interest in several research fields. Asthma patients have been reported to present highly variable outcomes due to the heterogeneity of the disease. For example, the Th2 response in patients with allergic asthma is capable of decreasing Th1 activation in COVID-19, preventing the onset of a cytokine storm; additionally, IL-...
RASAYAN Journal of Chemistry
Innumerable personages are associated with susceptibility to the COVID-19 pandemic viral infection evolution, which has globally overblown the healthcare facilities. Following the emergence of respiratory syndrome coronavirus, 2019- nCoV delineates as a third major emergence of a novel coronavirus. β-coronavirus having suspected origin from bat comprehend congestion of the respiratory system, indicating a worldwide life threat to around 235 million asthma patients’ existents as per WHO records. This review aims to investigate the risk constituents involved in virus-induced asthma, its management and prevention, origin, and transmission of coronavirus, including the relationship between different CoV infections. This review culminated the role of cytokines and chemokines and others found in COVID19 patients, which could directly or indirectly affect the smooth muscle contractility reasoned to promote asthma severity, but this still remains unknown. The research highlights how essenti...
Asthma as A Comorbid Disease in COVID-19
Asthma Allergy Immunology, 2020
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that causes coronavirus disease 2019 (COVID-19). In terms of asthma and COVID-19, there is also a risk of experiencing an asthma exacerbation triggered by coronavirus infection beyond the direct risk of the infection itself. As a comorbid disease, the prevalence of COVID-19 infection in asthma patients is not clear. In addition, the influence of asthma on the severity of COVID-19 has not been reported. The aim of this review was to summarize the reported worldwide data about the prevalence and the clinical characteristics of patients with asthma during COVID-19 infection.
Asthma and COVID-19: a dangerous liaison?
Asthma Research and Practice, 2021
The coronavirus disease 2019 (COVID-19) pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provoked the most striking international public health crisis of our time. COVID-19 can cause a range of breathing problems, from mild to critical, with potential evolution to respiratory failure and acute respiratory distress syndrome. Elderly adults and those affected with chronic cardiovascular, metabolic, and respiratory conditions carry a higher risk of severe COVID-19. Given the global burden of asthma, there are well-founded concerns that the relationship between COVID-19 and asthma could represent a “dangerous liaison”.Here we aim to review the latest evidence on the links between asthma and COVID-19 and provide reasoned answers to current concerns, such as the risk of developing SARS-CoV-2 infection and/or severe COVID-19 stratified by asthmatic patients, the contribution of type-2 vs. non-type-2 asthma and asthma-COPD overlap to the risk of COVI...
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)
Allergy, 2020
To the Editor, A novel strain of human coronaviruses, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), named by the International Committee on Taxonomy of Viruses (ICTV), 1 has recently emerged and caused an infectious disease. This disease is referred to as the "coronavirus disease 2019" (COVID-19) by the World Health Organization (WHO). 2 The US Centers for Disease Control and Prevention (CDC) have proposed that "People with moderate to severe asthma may be at higher risk of getting very sick from COVID-19. COVID-19 can affect your respiratory tract (nose, throat, lungs), cause an asthma attack and possibly lead to pneumonia and acute respiratory disease." (May 24, 2020). (https://www.cdc.gov/coron aviru s/2019-ncov/need-extra-preca ution s/asthma.html) On the other hand, in the UK, NICE proposes rapid guidelines for severe asthma (https://www.guide lines.co.uk/covid-19-rapid-guide line-sever e-asthm a/455275.article).
Asthma and COVID-19: What do we know
Tuberk Toraks. 2020 Jul;68(2):141-147. , 2020
Asthma and COVID-19: What do we know? There are limited data about the coexistence of asthma and the Coronavirus disease-2019 (COVID-19). The COVID-19 pandemic is a new disease for the whole world. In this study, we aimed to examine the published case series with the COVID-19 and asthma coexistence, by reviewing existing studies and other publications. We discussed the suggestions of guidelines such as The Global Initiative for Asthma (GINA), The National Institute for Health and Care Excellence (NICE), and the Canadian Respiratory Guideline about the management of asthma during the COVID-19 pandemic and the experiences of different countries. We analyzed the publications, reports, and expert opinions about asthma and COVID-19, that were released and expressed from the onset of the disease in Wuhan. In this review, we aimed to summarize the approach to patients with asthma during the pandemic and to make recommendations concerning it.
COVID-19 and bronchial asthma: current perspectives
Global Health & Medicine, 2021
Angiotensin converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2), two receptors on the cell membrane of bronchial epithelial cells, are indispensable for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ACE2 receptor is increased among aged, males, and smokers. As smoking upsurges ACE2 expression, chronic obstructive pulmonary disease (COPD) patients are prone to SARS-CoV-2 infection, and are at a higher risk for severe forms of COVID-19 (coronavirus disease 2019) once infected. The expression of ACE2 and TMPRSS2 in asthma patients is identical (or less common) to that of healthy participants. ACE2 especially, tends to be low in patients with strong atopic factors and in those with poor asthma control. Therefore, it could be speculated that asthma patients are not susceptible to COVID-19. Epidemiologically, asthma patients are less likely to suffer from COVID-19, and the number of hospitalized patients due to exacerbation of asthma in Japan is also clearly reduced during the COVID-19 pandemic; therefore, they are not aggravating factors for COVID-19. Related academic societies in Japan and abroad still lack clear evidence regarding asthma treatment during the COVID-19 pandemic, and recommend that regular treatment including biologics for severe patients be continued.